Avantor, Inc. (NYSE:AVTR) Receives $27.57 Average Target Price from Brokerages

Shares of Avantor, Inc. (NYSE:AVTR) have received an average recommendation of “Moderate Buy” from the fifteen brokerages that are covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $27.57.

AVTR has been the topic of a number of research reports. Barclays dropped their target price on Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. Morgan Stanley increased their price objective on Avantor from $28.00 to $29.00 and gave the stock an “overweight” rating in a report on Monday, July 29th. Stifel Nicolaus increased their price objective on Avantor from $27.00 to $28.00 and gave the stock a “buy” rating in a report on Monday, July 29th. Royal Bank of Canada restated an “outperform” rating and issued a $34.00 price objective on shares of Avantor in a report on Thursday, September 26th. Finally, TD Cowen increased their price objective on Avantor from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Monday, July 29th.

Avantor Price Performance

Shares of AVTR opened at $22.59 on Wednesday. The company has a market capitalization of $15.37 billion, a price-to-earnings ratio of 49.11, a P/E/G ratio of 2.73 and a beta of 1.35. Avantor has a fifty-two week low of $18.08 and a fifty-two week high of $28.00. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06. The business’s 50-day moving average is $24.91 and its 200-day moving average is $24.12.

Insider Buying and Selling at Avantor

In other news, CAO Steven W. Eck sold 3,525 shares of the stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $25.06, for a total value of $88,336.50. Following the completion of the sale, the chief accounting officer now directly owns 29,544 shares of the company’s stock, valued at approximately $740,372.64. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.30% of the company’s stock.

Institutional Investors Weigh In On Avantor

Hedge funds have recently modified their holdings of the business. Versant Capital Management Inc boosted its position in shares of Avantor by 2,003.6% in the second quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock valued at $25,000 after acquiring an additional 1,102 shares during the period. Blue Trust Inc. lifted its position in Avantor by 1,830.3% in the second quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock worth $31,000 after purchasing an additional 1,391 shares during the period. UMB Bank n.a. bought a new position in Avantor in the third quarter worth $49,000. Nisa Investment Advisors LLC lifted its position in Avantor by 69.6% in the third quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock worth $53,000 after purchasing an additional 835 shares during the period. Finally, GAMMA Investing LLC lifted its position in Avantor by 89.9% in the third quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock worth $70,000 after purchasing an additional 1,285 shares during the period. 95.08% of the stock is owned by institutional investors.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.